What the research actually shows

Peptide evidence review

Tesamorelin is FDA-approved — but only for HIV-associated lipodystrophy, where it genuinely reduces visceral fat in replicated Phase-3 trials. We separate that approved, evidenced core from the off-label anti-aging and fat-loss use that rides on it, and surface the durability catch (the fat returns when you stop), the IGF-1, glucose, and neoplasm warnings, and the WADA ban that applies even to an approved drug.

Peptide evidence review

TB-500's recovery use rests on animal data and a single rat ligament study; the human trials studied a different molecule for other conditions, and the well-powered ones failed. We grade each claim by tier and surface the FDA listing and the WADA ban.

Peptide evidence review

BPC-157's healing evidence is almost entirely from animal studies; the only human data is one small uncontrolled case series. We grade each claim by tier, separate animal from human, and surface the FDA Category-2 listing and the WADA ban.

Peptide evidence review

In healthy adults, the with-DAC form of CJC-1295 raises growth hormone and IGF-1 for days, a biomarker, not a proven benefit. We grade each claim by tier, separate the with-DAC research form from the no-DAC form usually sold, report what clinics and communities actually do with it, and surface the halted 2006 trial, the death, the FDA non-approval, and the WADA ban.

Peptide evidence review

GHK-Cu has real human evidence applied to the skin and none injected. We lead with the actual trial numbers, grade each claim by tier, separate the topical lane from the injected lane, and surface the copper-safety and regulatory status.

Peptide evidence review

Ipamorelin transiently raises growth hormone in healthy men, a real biomarker effect, but no human study shows that produces fat loss, muscle, anti-aging, or any benefit. We grade each claim by tier, separate human from animal evidence, and surface the failed trial, the FDA non-approval, and the WADA ban.